Abstract

The field of prostate cancer has been the subject of extensive research that has resulted in important discoveries and shaped our appreciation of this disease and its management. Advances in our understanding of the epidemiology, natural history, anatomy, detection, diagnosis, grading, staging, imaging, and management of prostate cancer have changed clinical practice and influenced guideline recommendations. The development of the Gleason score and subsequent modifications enabled accurate prediction of prognosis. Increased anatomical understanding and improved surgical techniques resulted in the development of nerve-sparing surgery for radical prostatectomy. The advent of active surveillance has changed the management of low-risk disease, and chemotherapy and hormonal therapy have improved the outcomes of patients with distant disease. Ongoing research and clinical trials are expected to yield more practice-changing results in the near future.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29 (2015).

  2. 2.

    Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 136, E359–E386 (2015).

  3. 3.

    Tasian, G. E. et al. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostat. Dis. 15, 189–194 (2012).

  4. 4.

    Shoag, J. et al. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J. Urol. 196, 1047–1052 (2016).

  5. 5.

    Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26 (2016).

  6. 6.

    Howard, D. H. Declines in prostate cancer incidence after changes in screening recommendations. Arch. Intern. Med. 172, 1267–1268 (2012).

  7. 7.

    Potosky, A. L., Miller, B. A., Albertsen, P. C. & Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. JAMA 273, 548–552 (1995).

  8. 8.

    Gaylis, F. D. et al. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. Urol. Oncol. 35, 663.e1–663 (2017).

  9. 9.

    Cooperberg, M. R. The new US Preventive Services Task Force “C” draft recommendation for prostate cancer screening. Eur. Urol. 72, 326–328 (2017).

  10. 10.

    US Preventive Services Task Force. Draft prostate cancer screening recommendation statement (US Preventive Services, 2017).

  11. 11.

    Patel, A. R. & Klein, E. A. Risk factors for prostate cancer. Nat. Clin. Practice Urol. 6, 87 (2009).

  12. 12.

    Odedina, F. T. et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect. Agent Cancer. 4 (Suppl. 1), S2 (2009).

  13. 13.

    Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B. & Walsh, P. C. Family history and the risk of prostate cancer. Prostate 17, 337–347 (1990).

  14. 14.

    Bancroft, E. K. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur. Urol. 66, 489–499 (2014).

  15. 15.

    Albertsen, P. C., Hanley, J. A., Gleason, D. F. & Barry, M. J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280, 975–980 (1998).

  16. 16.

    Albertsen, P. C., Hanley, J. A. & Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095–2101 (2005).

  17. 17.

    Johansson, J. E. et al. Natural history of early, localized prostate cancer. JAMA 291, 2713–2719 (2004).

  18. 18.

    Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591–1597 (1999).

  19. 19.

    Wang, M. C., Valenzuela, L. A., Murphy, G. P. & Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol. 17, 159–163 (1979).

  20. 20.

    Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).

  21. 21.

    Carter, H. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267, 2215–2220 (1992).

  22. 22.

    Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190, 419–426 (2013).

  23. 23.

    Wolf, A. M. et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60, 70–98 (2010).

  24. 24.

    Cooner, W. H. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 143, 1146–1152; discussion 52–54 (1990).

  25. 25.

    Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).

  26. 26.

    Catalona, W. J. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151, 1283–1290 (1994).

  27. 27.

    Thompson, I. M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N. Engl. J. Med. 350, 2239–2246 (2004).

  28. 28.

    Mottet, N. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71, 618–629 (2017).

  29. 29.

    Carroll, P. R. et al. NCCN Guidelines insights: prostate cancer early detection, version 2.2016. J. Natl Compr. Cancer Netw. 14, 509–519 (2016).

  30. 30.

    Draisma, G. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl Cancer Inst. 95, 868–878 (2003).

  31. 31.

    Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).

  32. 32.

    Schroder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).

  33. 33.

    Moyer, V. A. et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).

  34. 34.

    Jemal, A. et al. Prostate cancer incidence and psa testing patterns in relation to uspstf screening recommendations. JAMA 314, 2054–2061 (2015).

  35. 35.

    Bhindi, B. et al. Impact of the US Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J. Urol. 193, 1519–1524 (2015).

  36. 36.

    Weiner, A. B., Matulewicz, R. S., Eggener, S. E. & Schaeffer, E. M. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 19, 395–397 (2016).

  37. 37.

    Hu, J. C. et al. Increase in prostate cancer distant metastases at diagnosis in the united states. JAMA Oncol. 3, 705–707 (2017).

  38. 38.

    Rezaee, M. E., Ward, C. E., Odom, B. D. & Pollock, M. Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012. Prev. Med. 82, 73–76 (2016).

  39. 39.

    Bibbins-Domingo, K., Grossman, D. C. & Curry, S. J. The US preventive services task force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA 317, 1949–1950 (2017).

  40. 40.

    US Preventive Services Task Force et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319, 1901–1913 (2018).

  41. 41.

    Schroder, F. H. et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur. Urol. 62, 745–752 (2012).

  42. 42.

    Schroder, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014).

  43. 43.

    Martin, R. M. et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the cap randomized clinical trial. JAMA 319, 883–895 (2018).

  44. 44.

    Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).

  45. 45.

    Thompson, I. M. et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369, 603–610 (2013).

  46. 46.

    Unger, J. M. et al. Using medicare claims to examine long-term prostate cancer risk of finasteride in the prostate cancer prevention trial. Natl Cancer Inst. https://doi.org/10.1093/jnci/djy035 (2018).

  47. 47.

    Kramer, B. S. et al. Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27, 1502–1516 (2009).

  48. 48.

    Lippman, S. M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39–51 (2009).

  49. 49.

    Klein, E. A. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549–1556 (2011).

  50. 50.

    McNeal, J. E. The zonal anatomy of the prostate. Prostate 2, 35–49 (1981).

  51. 51.

    Kourambas, J., Angus, D. G., Hosking, P. & Chou, S. T. A histological study of Denonvilliers’ fascia and its relationship to the neurovascular bundle. Br. J. Urol. 82, 408–410 (1998).

  52. 52.

    Costello, A. J., Brooks, M. & Cole, O. J. Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int. 94, 1071–1076 (2004).

  53. 53.

    Walsh, P. C. & Donker, P. J. Impotence following radical prostatectomy: insight into etiology and prevention. J. Urol. 128, 492–497 (1982).

  54. 54.

    Walsh, P. C. & Lepor, H. The role of radical prostatectomy in the management of prostatic cancer. Cancer 60, 526–537 (1987).

  55. 55.

    Walsh, P. C., Lepor, H. & Eggleston, J. C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4, 473–485 (1983).

  56. 56.

    Barringer, B. S. Carcinoma of the prostate. Surg. Gynecol. Obstet. 34, 168–176 (1922).

  57. 57.

    Young, H. H. & Davis, D. M. Young’s Practice of Urology (Philadelphia & London, WB Saunders, 1926).

  58. 58.

    Hodge, K. K., McNeal, J. E. & Stamey, T. A. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J. Urol. 142, 66–70 (1989).

  59. 59.

    Levine, M. A., Ittman, M., Melamed, J. & Lepor, H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J. Urol. 159, 471–475; discussion 5–6 (1998).

  60. 60.

    Presti, J. C. et al. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J. Urol. 169, 125–129 (2003).

  61. 61.

    Siddiqui, M. M. et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313, 390–397 (2015).

  62. 62.

    Chang, D. T. S., Challacombe, B. & Lawrentschuk, N. Transperineal biopsy of the prostate — is this the future? Nat. Rev. Urol. 10, 690 (2013).

  63. 63.

    Wright, J. L. & Ellis, W. J. Improved prostate cancer detection with anterior apical prostate biopsies. Urol. Oncol. 24, 492–495 (2006).

  64. 64.

    Bott, S. R. et al. Extensive transperineal template biopsies of prostate: modified technique and results. Urology 68, 1037–1041 (2006).

  65. 65.

    Hu, Y. et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int. 110, 812–820 (2012).

  66. 66.

    Grummet, J. P. et al. Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 114, 384–388 (2014).

  67. 67.

    Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).

  68. 68.

    Gleason, D. F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 50, 125–128 (1966).

  69. 69.

    Gleason, D. in Pathology of the Prostate (ed. Bostwick D.G.) 83–93 (Churchill Livingstone, 1990).

  70. 70.

    Humphrey, P. A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 17, 292–306 (2004).

  71. 71.

    Delahunt, B., Miller, J., Srigley, J. R., Evans, A. J. & Samaratunga, H. Gleason grading: past, present and future. Histopathology 60, 75–86 (2012).

  72. 72.

    Billis, A., et al. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J. Urol. 180, 548–552; discussion 52–53 (2008).

  73. 73.

    Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 (2016).

  74. 74.

    Wymenga, L. F., Boomsma, J. H., Groenier, K., Piers, D. A. & Mensink, H. J. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 88, 226–230 (2001).

  75. 75.

    Sanda, M. G. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J. Urol. https://doi.org/10.1016/j.juro.2017.11.095 (2017).

  76. 76.

    Taneja, S. S. Imaging in the diagnosis and management of prostate cancer. Rev. Urol. 6, 101–113 (2004).

  77. 77.

    Umbehr, M. H., Muntener, M., Hany, T., Sulser, T. & Bachmann, L. M. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur. Urol. 64, 106–117 (2013).

  78. 78.

    Afshar-Oromieh, A. et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nuclear Med. Mol. Imag. 42, 197–209 (2015).

  79. 79.

    Eiber, M. et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 55, 668–674 (2015).

  80. 80.

    Boorjian, S. A., Karnes, R. J., Rangel, L. J., Bergstralh, E. J. & Blute, M. L. Mayo Clinic validation of the D’amico risk group classification for predicting survival following radical prostatectomy. J. Urol. 179, 1354–1360; discussion 60–61 (2008).

  81. 81.

    Lee, S. E. et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int. 105, 1526–1530 (2010).

  82. 82.

    D’Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969–974 (1998).

  83. 83.

    Partin, A. W. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277, 1445–1451 (1997).

  84. 84.

    Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. & Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766–771 (1998).

  85. 85.

    Kattan, M. W., Wheeler, T. M. & Scardino, P. T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 17, 1499–1507 (1999).

  86. 86.

    Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl Cancer Inst. 98, 715–717 (2006).

  87. 87.

    Cooperberg, M. R. et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173, 1938–1942 (2005).

  88. 88.

    Cooperberg, M. R., Hilton, J. F. & Carroll, P. R. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117, 5039–5046 (2011).

  89. 89.

    Brajtbord, J. S., Leapman, M. S. & Cooperberg, M. R. The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies. Eur. Urol. 71, 705–709.

  90. 90.

    Hricak, H. et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162, 331–336 (1987).

  91. 91.

    Kurhanewicz, J., Swanson, M. G., Nelson, S. J. & Vigneron, D. B. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magnet. Resonance Imag. 16, 451–463 (2002).

  92. 92.

    Langer, D. L. et al. Prostate cancer detection with multi-parametric MRI: Logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J. Magnet. Resonance Imag. 30, 327–334 (2009).

  93. 93.

    Tanimoto, A., Nakashima, J., Kohno, H., Shinmoto, H. & Kuribayashi, S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J. Magnet. Resonance Imag. 25, 146–152 (2007).

  94. 94.

    Barentsz, J. O. et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746–757 (2012).

  95. 95.

    Vargas, H. A. et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur. Radiol. 26, 1606–1612 (2016).

  96. 96.

    Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

  97. 97.

    Fulgham, P. F. et al. AUA policy statement on the use of multiparametric magnetic resonance imaging in the diagnosis, staging and management of prostate cancer. J. Urol. 198, 832–838 (2017).

  98. 98.

    Newschaffer, C. J., Otani, K., McDonald, M. K. & Penberthy, L. T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J. Natl Cancer Inst. 92, 613–621 (2000).

  99. 99.

    Montie, J. E. & Smith, J. A. Whitmoreisms: memorable quotes from Willet F. Whitmore Jr, M. D. Urology 63, 207–209 (2004).

  100. 100.

    Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl Cancer Inst. 100, 1144–1154 (2008).

  101. 101.

    Johansson, E. et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 12, 891–899 (2011).

  102. 102.

    Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

  103. 103.

    Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).

  104. 104.

    Wilt, T. J. et al. Follow-up of prostatectomy versus observation for early prostate cancer. N. Engl. J. Med. 377, 132–142 (2017).

  105. 105.

    Choo, R. et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 167, 1664–1669 (2002).

  106. 106.

    Lawrentschuk, N. & Klotz, L. Active surveillance for low-risk prostate cancer: an update. Nat. Rev. Urol. 8, 312–320 (2011).

  107. 107.

    Parker, C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 5, 101–106 (2004).

  108. 108.

    Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2015).

  109. 109.

    Tosoian, J. J. et al. Active surveillance of prostate cancer: use, outcomes, imaging, and diagnostic tools. Am. Soc. Clin. Oncol. 35, e235–e245 (2016).

  110. 110.

    Adolfsson, J. Watchful waiting and active surveillance: the current position. BJU Int. 102, 10–14 (2008).

  111. 111.

    Young, H. H. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. J. Urol. 168, 914–921 (2002).

  112. 112.

    Millin T. Retropubic urinary surgery. London: Livingstone 35, 442 (1947).

  113. 113.

    Millin, T. Retropubic prostatectomy a new extravesical technique: report on 20 cases. Lancet. 246, 693–696 (1945).

  114. 114.

    Walsh, P. C. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J. Urol. 177, 1632–1635 (2007).

  115. 115.

    Saranchuk, J. W. et al. Achieving optimal outcomes after radical prostatectomy. J. Clin. Oncol. 23, 4146–4151 (2005).

  116. 116.

    Schuessler, W. W., Kavoussi, L. R., Clayman, R. V. & Vancaille, T. Laparoscopic radical prostatectomy: initial case report. J. Urol. 147, 246A (1992).

  117. 117.

    Guillonneau, B. & Vallancien, G. Laparoscopic radical prostatectomy: the Montsouris technique. J. Urol. 163, 1643–1649 (2000).

  118. 118.

    Carlucci, J. R., Nabizada-Pace, F. & Samadi, D. B. Robot-assisted laparoscopic radical prostatectomy: technique and outcomes of 700 cases. Int. J. Biomed. Sci. 5, 201–208 (2009).

  119. 119.

    Abbou, C. C. et al. Laparoscopic radical prostatectomy with a remote controlled robot. J. Urol. 165, 1964–1966 (2001).

  120. 120.

    Menon, M., Hemal, A. K. & VIP Team. Vattikuti Institute prostatectomy: a technique of robotic radical prostatectomy: experience in more than 1000 cases. J. Endourol. 18, 611–619 (2004).

  121. 121.

    Yaxley, J. W. et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 388, 1057–1066 (2016).

  122. 122.

    Glickman, L., Godoy, G. & Lepor, H. Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J. Urol. 181, 731–735 (2009).

  123. 123.

    Bagshaw, M. A., Kaplan, H. S. & Sagerman, R. H. Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 85, 121–129 (1965).

  124. 124.

    Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).

  125. 125.

    D’Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M. & Kantoff, P. W. Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA 299, 289–295 (2008).

  126. 126.

    Denham, J. W. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 6, 841–850 (2005).

  127. 127.

    Horwitz, E. M. et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26, 2497–2504 (2008).

  128. 128.

    Jones, C. U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365, 107–118 (2011).

  129. 129.

    Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285–1290 (2005).

  130. 130.

    Roach, M. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585–591 (2008).

  131. 131.

    Bolla, M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337, 295–300 (1997).

  132. 132.

    Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243–1252 (2001).

  133. 133.

    Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301–308 (2009).

  134. 134.

    Warde, P. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378, 2104–2111 (2011).

  135. 135.

    Zelefsky, M. J., Fuks, Z. & Leibel, S. A. Intensity-modulated radiation therapy for prostate cancer. Semin. Radiat. Oncol. 12, 229–237 (2002).

  136. 136.

    Das, S. et al. Comparison of image-guided radiotherapy technologies for prostate cancer. Am. J. Clin. Oncol. 37, 616–623 (2014).

  137. 137.

    Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924–2930 (2009).

  138. 138.

    Wiegel, T. et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur. Urol. 66, 243–250 (2014).

  139. 139.

    Thompson, I. M. et al. Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956–962 (2009).

  140. 140.

    Thompson, I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329–2335 (2006).

  141. 141.

    Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572–578 (2005).

  142. 142.

    Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380, 2018–2027 (2012).

  143. 143.

    Morris, W. J. et al. Low-dose-rate brachytherapy is superior to dose-escalated EBRT for unfavourable risk prostate cancer: the results of the ASCENDE-RT* randomized control trial. Brachytherapy 14, S12 (2015).

  144. 144.

    Stock, R. G., Cahlon, O., Cesaretti, J. A., Kollmeier, M. A. & Stone, N. N. Combined modality treatment in the management of high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 1352–1359 (2004).

  145. 145.

    Dearnaley, D. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 17, 1047–1060 (2016).

  146. 146.

    Huggins, C., Stevens, R. E. Jr & Hodges, C. V. Studies on prostatic cancer. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209–223 (1941).

  147. 147.

    Huggins, C., Stevens, R. E. Jr & Hodges, C. V. Studies on prostatic cancer. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Arch. Surg. 43, 209–223 (1941).

  148. 148.

    Ahmann, F. R. et al. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J. Clin. Oncol. 5, 912–917 (1987).

  149. 149.

    Goldenberg, S. L. & Bruchovsky, N. Use of cyproterone acetate in prostate cancer. Urol. Clin. North Am. 18, 111–122 (1991).

  150. 150.

    Labrie, F. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 5, 267–275 (1982).

  151. 151.

    Crawford, E. D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419–424 (1989).

  152. 152.

    Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).

  153. 153.

    Messing, E. M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341, 1781–1788 (1999).

  154. 154.

    Messing, E. M. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7, 472–479 (2006).

  155. 155.

    Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).

  156. 156.

    Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).

  157. 157.

    Walker, L. M., Tran, S. & Robinson, J. W. Luteinizing hormone — releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin. Genitourin. Cancer 11, 375–384 (2013).

  158. 158.

    Green, H. J. et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 93, 975–979 (2004).

  159. 159.

    Rhee, H. et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 115 (Suppl. 5), 3–13 (2015).

  160. 160.

    Keating, N. L., O’Malley, A. J., Freedland, S. J. & Smith, M. R. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur. Urol. 64, 159–166 (2013).

  161. 161.

    Hamilton, E. J. et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J. Clin. Endocrinol. Metab. 95, E456–463 (2010).

  162. 162.

    Cornford, P. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol. 71, 630–642 (2017).

  163. 163.

    Berthold, D. R., Sternberg, C. N. & Tannock, I. F. Management of advanced prostate cancer after first-line chemotherapy. J. Clin. Oncol. 23, 8247–8252 (2005).

  164. 164.

    Wozniak, A. J. et al. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer 71, 3975–3978 (1993).

  165. 165.

    Sridhar, S. S. et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur. Urol. 65, 289–299 (2014).

  166. 166.

    Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).

  167. 167.

    Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

  168. 168.

    Berthold, D. R. et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin. Cancer Res. 14, 2763–2767 (2008).

  169. 169.

    de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

  170. 170.

    Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).

  171. 171.

    Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).

  172. 172.

    James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 387, 1163–1177 (2016).

  173. 173.

    James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

  174. 174.

    Fizazi, K. et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. J. Clin. Oncol. 35, LBA3 (2017).

  175. 175.

    Mohler, J. L. et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440–448 (2004).

  176. 176.

    Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).

  177. 177.

    Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534–540 (1990).

  178. 178.

    Pienta, K. J. & Bradley, D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12, 1665–1671 (2006).

  179. 179.

    Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

  180. 180.

    Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305–2313 (2009).

  181. 181.

    Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

  182. 182.

    Shore, N. D. et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 17, 153–163 (2016).

  183. 183.

    Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

  184. 184.

    Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

  185. 185.

    Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16, 152–160 (2015).

  186. 186.

    Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

  187. 187.

    Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

  188. 188.

    Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458–1468 (2002).

  189. 189.

    Saad, F. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96, 879–882 (2004).

  190. 190.

    Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).

  191. 191.

    Litwin, M. S. et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med. Care. 36, 1002–1012 (1998).

  192. 192.

    Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M. & Sanda, M. G. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56, 899–905 (2000).

  193. 193.

    Szymanski, K. M., Wei, J. T., Dunn, R. L. & Sanda, M. G. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument (epic-26) for measuring health-related quality of life among prostate cancer survivors. Urology 76, 1245–1250 (2010).

  194. 194.

    Resnick, M. J. et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 368, 436–445 (2013).

  195. 195.

    Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J. & McKinlay, J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 151, 54–61 (1994).

  196. 196.

    Kim, E. H. & Andriole, G. L. A simplified prostate cancer grading system. Nat. Rev. Urol. 12, 601–602 (2015).

  197. 197.

    Epstein, J. I., Walsh, P. C., Carmichael, M. & Brendler, C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271, 368–374 (1994).

  198. 198.

    de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

  199. 199.

    Penson, D. F. et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J. Clin. Oncol. 34, 2098–2106 (2016).

  200. 200.

    Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

Download references

Author information

Affiliations

  1. Department of Urology, University of Minnesota, Minneapolis, MN, USA

    • Niranjan J. Sathianathen
    •  & Badrinath R. Konety
  2. University of Melbourne, Department of Surgery, Urology Unit and Olivia Newton-John Cancer Research Institute Austin Health, Melbourne, Victoria, Australia

    • Niranjan J. Sathianathen
    •  & Nathan Lawrentschuk
  3. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    • Niranjan J. Sathianathen
    •  & Nathan Lawrentschuk
  4. Department of Radiation Oncology and Developmental Radiotherapeutics, University of British Columbia, Kelowna, British Columbia, Canada

    • Juanita Crook
  5. Division of Urology, Centre Hospitalier de l’Université de Montreal, University of Montreal, Montreal, Québec, Canada

    • Fred Saad

Authors

  1. Search for Niranjan J. Sathianathen in:

  2. Search for Badrinath R. Konety in:

  3. Search for Juanita Crook in:

  4. Search for Fred Saad in:

  5. Search for Nathan Lawrentschuk in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Niranjan J. Sathianathen.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41585-018-0060-7